2015;373:2117 28. 155. Neal B, Perkovic V, Mahaffey KW, et al. Canagli- ozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644 57. 156. Wiviott SD, Raz I, Bonaca MP, et al. Dapagli ozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347 57. 157. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagli ozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436 46. 158. January CT, Wann LS, Calkins H, et al. 2019 AHA/ ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial brillation: a report of the American College of Cardi- ology/American Heart Association Task Force on Clin- ical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104 32. 159. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial brillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1 76. 160. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70: 252 89. 161. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:e57 185. 162. Bonow RO, O Gara PT, Adams DH, et al. 